Avacta Therapeutics
  • About
  • Our Science
  • Pipeline
  • News
  • Investors
  • Careers
  • Contact
  • About
    • About Avacta
    • Leadership
    • Scientific Resources
    • Intellectual Property
  • Our Science
    • Our Science
    • 1st Gen
    • 2nd Gen
    • 3rd Gen
    • Partners
    • Clinical trials
  • Pipeline
  • News
  • Investors
    • Investors
    • Key info
    • Corporate Governance
    • Resources
    • Share price
    • RNS News
    • Events
    • Research
  • Careers
    • Job vacancies
    • Benefits of working at Avacta
  • Contact
  • About
    • About Avacta
    • Leadership
    • Scientific Resources
    • Intellectual Property
  • Our Science
    • Our Science
    • 1st Gen
    • 2nd Gen
    • 3rd Gen
    • Partners
    • Clinical trials
  • Pipeline
  • News
  • Investors
    • Investors
    • Key info
    • Corporate Governance
    • Resources
    • Share price
    • RNS News
    • Events
    • Research
  • Careers
    • Job vacancies
    • Benefits of working at Avacta
  • Contact
Home News
filter by: view all | Blogs | Diagnostics | Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics

News

30 Sep 2021

Interim Results for the Period Ended 30 June 2021 and Business Update

Investors
29 Sep 2021

Achievement of Pre-clinical Development Milestone in LG Chem Life Sciences Partnership

Investors | Therapeutics
09 Sep 2021

Notice of Results and Investor Presentation

Investors
06 Sep 2021

Avacta announces new appointments to the Scientific Advisory Board of its Therapeutics Division

Investors | Therapeutics
02 Sep 2021

Appointment of Dr Fiona McLaughlin as Chief Scientific Officer of Avacta’s Therapeutics Division

Investors | Therapeutics
18 Aug 2021

Directorate Change

Investors
11 Aug 2021

Avacta Announces First Patient Dosed in AVA6000 Pro-Doxorubicin Phase 1 Clinical Trial

Investors | Therapeutics
04 Aug 2021

Update on AffiDX® SARS-CoV-2 Antigen Lateral Flow Test

Diagnostics | Investors
29 Jun 2021

AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Detects Delta Variant

Diagnostics | Investors
28 Jun 2021

Result of Annual General Meeting

Investors

Posts navigation

Older posts
Newer posts
Avacta Therapeutics
  • Diagnostics
  • Terms of Use
  • Terms & Conditions
  • Privacy Policy
  • Intellectual Property
  • Corporate Responsibility
  • Contact Us

Avacta Group plc

Scale Space,  White City
Imperial College Campus
58 Wood Lane
London
W12 7RZ

+44 (0)20 3911 0353

Investor Enquiries

ICR Consilium
85 Gresham Street
London
EC2V 7NQ

 

Email

Twitter | Linkedin

©2025 Avacta Therapeutics. Registered company no. 06605196.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok